Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance.

Novo Nordisk's U.S.-listed shares rose Wednesday morning as it reported better third-quarter profits than expected, though sales of its drugs including popular weight-loss treatments Ozempic and Wegovy grew less than expected.

German software developer TeamViewer lowered its full-year revenue outlook on Wednesday, citing that foreign exchange headwinds from 2023 billings could likely have a negative impact of up to 11 million euros ($11.84 million).The company, which specialises in cloud-based technologies, now expects its rev

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a generic version of a Novo Nordisk diabetes and weight-loss drug as early as next year.